169 0 Kommentare Senseonics Announces UnitedHealthcare Coverage of Eversense E3 CGM for Adults with Diabetes

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that UnitedHealthcare, the largest health insurance company in the United States, will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes.

"The policy update from UnitedHealthcare marks an important milestone for increased access to long-term CGM for people with diabetes. With the addition of UnitedHealthcare, we are nearing all insured adults in the United States having access to the Eversense E3 CGM System," said Tim Goodnow, PhD, President and Chief Executive Officer for Senseonics. "The Eversense E3 CGM System enables patients and health care providers to effectively manage diabetes for 6 months with sustained accuracy and a removable smart transmitter that provides vibratory alerts and comprehensive data regarding glucose values and trends. We are excited about the expanded opportunity to provide these differentiated benefits of Eversense to more people with diabetes in collaboration with our global commercial partner Ascensia Diabetes Care."

UnitedHealthcare is the largest health insurance company in the United States, with over 45 million covered lives. It offers a full range of health benefits, enabling affordable coverage, simplifying the healthcare experience, and delivering access to high-quality care. UnitedHealthcare’s updated CGM coverage policy can be found here.

This recent coverage decision adds to the extensive number of payers who include Eversense in their CGM coverage policies that now benefit approximately 300 million covered lives, as well as paying for the healthcare provider's time for the in-office sensor insertion. This allows Ascensia Diabetes Care (ADC), our global commercial partner, to introduce the Eversense CGM System to more people living with diabetes.

Lesen Sie auch

Jetzt kommen Chancen

Patients who are interested in getting started with Eversense now can sign up at https://www.ascensiadiabetes.com/eversense/#get-started. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/. Alternatively, contact 844-SENSE4U (844-736-7348) to learn more about the first and only long-term implantable CGM system.

Seite 1 von 3

Seite 2 ►